JY
BMY.RT

Jeff Yass’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Jeff Yass’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,974,708
Closed -$5.5M – 13257
2020
Q4 		$5.5M Sell
7,974,708
-1,944,731
-20% -$4.14M ﹤0.01% 3275
2020
Q3 		$22.3M Sell
9,919,439
-191,701
-2% -$547K ﹤0.01% 1392
2020
Q2 		$36.2M Sell
10,111,140
-2,856,357
-22% -$10.3M 0.01% 999
2020
Q1 		$49.3M Sell
12,967,497
-3,894,942
-23% -$12.8M 0.02% 664
2019
Q4 		$50.8M Buy
+16,862,439
New +$43.8M 0.01% 795

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Jeff Yass's BMY.RT Position: Q1 2021 in Review

Jeff Yass sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 7,974,708 shares — an estimated $5.5M sold.

Jeff Yass first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $50.8M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Jeff Yass reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Jeff Yass sold 7,974,708 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $5.5M.
  • Jeff Yass first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Jeff Yass's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $50.8M in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Susquehanna International Group's 13F filing for Q1 2021, filed 17 May 2021.